Joseph Stringer
Stock Analyst at Needham
(3.89)
# 559
Out of 4,945 analysts
308
Total ratings
45.05%
Success rate
10.91%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Stringer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CDTX Cidara Therapeutics | Maintains: Buy | $54 → $74 | $63.55 | +16.44% | 14 | Aug 8, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $377 → $478 | $442.73 | +7.97% | 23 | Jul 31, 2025 | |
| GILD Gilead Sciences | Upgrades: Buy | $133 | $119.02 | +11.75% | 7 | Jul 25, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $72 → $95 | $96.49 | -1.54% | 25 | Jul 9, 2025 | |
| STOK Stoke Therapeutics | Reiterates: Buy | $22 | $17.17 | +28.13% | 23 | Jul 1, 2025 | |
| PHAT Phathom Pharmaceuticals | Maintains: Buy | $28 | $10.47 | +167.43% | 52 | Jun 6, 2025 | |
| VIR Vir Biotechnology | Reiterates: Buy | $14 | $4.44 | +215.32% | 18 | May 22, 2025 | |
| ANNX Annexon | Maintains: Buy | $16 → $11 | $2.38 | +362.18% | 19 | May 13, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $40 → $29 | $27.62 | +5.00% | 20 | May 7, 2025 | |
| VRTX Vertex Pharmaceuticals | Reiterates: Hold | n/a | $390.30 | - | 6 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $55 | $42.85 | +28.35% | 21 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $60 | $46.07 | +30.24% | 17 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $90 | $31.43 | +186.35% | 17 | Apr 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $1.18 | - | 13 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $10 | $1.58 | +534.92% | 17 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $26.69 | - | 8 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $37 | $24.53 | +50.84% | 6 | Jan 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $18 | $12.94 | +39.10% | 2 | Aug 24, 2021 |
Cidara Therapeutics
Aug 8, 2025
Maintains: Buy
Price Target: $54 → $74
Current: $63.55
Upside: +16.44%
Alnylam Pharmaceuticals
Jul 31, 2025
Maintains: Buy
Price Target: $377 → $478
Current: $442.73
Upside: +7.97%
Gilead Sciences
Jul 25, 2025
Upgrades: Buy
Price Target: $133
Current: $119.02
Upside: +11.75%
Rhythm Pharmaceuticals
Jul 9, 2025
Maintains: Buy
Price Target: $72 → $95
Current: $96.49
Upside: -1.54%
Stoke Therapeutics
Jul 1, 2025
Reiterates: Buy
Price Target: $22
Current: $17.17
Upside: +28.13%
Phathom Pharmaceuticals
Jun 6, 2025
Maintains: Buy
Price Target: $28
Current: $10.47
Upside: +167.43%
Vir Biotechnology
May 22, 2025
Reiterates: Buy
Price Target: $14
Current: $4.44
Upside: +215.32%
Annexon
May 13, 2025
Maintains: Buy
Price Target: $16 → $11
Current: $2.38
Upside: +362.18%
Apellis Pharmaceuticals
May 7, 2025
Maintains: Buy
Price Target: $40 → $29
Current: $27.62
Upside: +5.00%
Vertex Pharmaceuticals
May 6, 2025
Reiterates: Hold
Price Target: n/a
Current: $390.30
Upside: -
Apr 30, 2025
Maintains: Buy
Price Target: $60 → $55
Current: $42.85
Upside: +28.35%
Apr 9, 2025
Reiterates: Buy
Price Target: $60
Current: $46.07
Upside: +30.24%
Apr 8, 2025
Reiterates: Buy
Price Target: $90
Current: $31.43
Upside: +186.35%
Mar 7, 2025
Reiterates: Hold
Price Target: n/a
Current: $1.18
Upside: -
Mar 4, 2025
Downgrades: Hold
Price Target: $10
Current: $1.58
Upside: +534.92%
Nov 8, 2024
Reiterates: Hold
Price Target: n/a
Current: $26.69
Upside: -
Jan 24, 2024
Upgrades: Buy
Price Target: $37
Current: $24.53
Upside: +50.84%
Aug 24, 2021
Maintains: Buy
Price Target: $32 → $18
Current: $12.94
Upside: +39.10%